175 related articles for article (PubMed ID: 15302229)
1. In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide.
Hinke SA; Manhart S; Speck M; Pederson RA; Demuth HU; McIntosh CH
Life Sci; 2004 Aug; 75(15):1857-70. PubMed ID: 15302229
[TBL] [Abstract][Full Text] [Related]
2. Localization of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor.
Gelling RW; Wheeler MB; Xue J; Gyomorey S; Nian C; Pederson RA; McIntosh CH
Endocrinology; 1997 Jun; 138(6):2640-3. PubMed ID: 9165060
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
4. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
Hinke SA; Manhart S; Kühn-Wache K; Nian C; Demuth HU; Pederson RA; McIntosh CH
J Biol Chem; 2004 Feb; 279(6):3998-4006. PubMed ID: 14610075
[TBL] [Abstract][Full Text] [Related]
5. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
6. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
8. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).
Hinke SA; Manhart S; Pamir N; Demuth H; W Gelling R; Pederson RA; McIntosh CH
Biochim Biophys Acta; 2001 May; 1547(1):143-55. PubMed ID: 11343800
[TBL] [Abstract][Full Text] [Related]
9. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
10. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
Green BD; Gault VA; O'harte FP; Flatt PR
Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
[TBL] [Abstract][Full Text] [Related]
11. Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.
Venneti KC; Malthouse JP; O'Harte FP; Hewage CM
Biochim Biophys Acta; 2011 Jul; 1814(7):882-8. PubMed ID: 21539943
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP).
Hinke SA; Gelling R; Manhart S; Lynn F; Pederson RA; Kühn-Wache K; Rosche F; Demuth HU; Coy D; McIntosh CH
Biol Chem; 2003 Mar; 384(3):403-7. PubMed ID: 12715891
[TBL] [Abstract][Full Text] [Related]
13. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
14. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.
Gault VA; Harriott P; Flatt PR; O'Harte FP
Biosci Rep; 2002; 22(5-6):523-8. PubMed ID: 12635849
[TBL] [Abstract][Full Text] [Related]
15. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
16. Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.
Gallwitz B; Witt M; Fölsch UR; Creutzfeldt W; Schmidt WE
J Mol Endocrinol; 1993 Jun; 10(3):259-68. PubMed ID: 8396943
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
[TBL] [Abstract][Full Text] [Related]
18. What do we know about the secretion and degradation of incretin hormones?
Deacon CF
Regul Pept; 2005 Jun; 128(2):117-24. PubMed ID: 15780431
[TBL] [Abstract][Full Text] [Related]
19. GIP(3-30)NH
Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
[TBL] [Abstract][Full Text] [Related]
20. Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand.
Yaqub T; Tikhonova IG; Lättig J; Magnan R; Laval M; Escrieut C; Boulègue C; Hewage C; Fourmy D
Mol Pharmacol; 2010 Apr; 77(4):547-58. PubMed ID: 20061446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
